{"nctId":"NCT01589523","briefTitle":"GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis","startDateStruct":{"date":"2006-02"},"conditions":["Bile Acid Synthesis Defect","Inborn Error of Bile Acid Metabolism","Inborn Error of Bile Acid Conjugation"],"count":5,"armGroups":[{"label":"GlycoCholic Acid, Study Drug","type":"EXPERIMENTAL","interventionNames":["Drug: Glycocholic Acid"]}],"interventions":[{"name":"Glycocholic Acid","otherNames":["Conjugated Cholic Acid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Confirmation of a diagnosis of an inborn error of bile acid synthesis/conjugation based upon urine analysis by FAB-MS.\n2. Any age\n3. Participant must be willing and able to comply with study assessments and procedures.\n4. The participant and/or parent/legal guardian must have signed the written informed consent document prior to study start.\n\nExclusion Criteria\n\n1\\. No confirmed diagnosis of inborn error of bile acid synthesis/conjugation based upon urine analysis by FAB-MS.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Week","maximumAge":"85 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Conjugated Cholic Acid (GCA) for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-chain Conjugation.","description":"This is the number of participants with bile acid amidation defects treated with oral glycocholic acid (15 milligrams/kilograms (mg/kg) of body weight/day (bw/day))","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Evaluation of Levels of Atypical Bile Acid Metabolites After GCA Treatment Compared","description":"Semi-quantitative descriptive evaluation of the levels of atypical bile acids in urine measured by mass spectrometry (FAB MS) based on a scale of 0 = absent or traces levels, 1 = low levels, 2 = moderate levels, 3 = high levels using the signal/noise ratio and intensity of ions. Atypical bile acids evaluated included m/z 407 (unconjugated cholic acid), m/z 471 (dihydroxy-choleanoic-sulfate) and m/z 583 (trihydroxy-choleanoic glucuronide).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Liver Function Tests of ALT From Baseline to Post-treatment","description":"Liver function tests Alanine Aminotransferease (ALT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":"10.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Change in Liver Function Test: AST From Baseline to Post-treatment","description":"Measure of Aspartate Aminotransferase (AST)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":"14.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Change in Vitamin D, 25-OH Measure From Baseline to Post-treatment","description":"Measure Vitamin D levels nanograms per milliliter (ng/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":"5.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":[]}}}